spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Almirall 

 HSMN NewsFeed - 25 Oct 2024
Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 7 Jun 2022
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 21 Dec 2021
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 16 Aug 2021
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 Mar 2021
Bioniz Therapeutics Appoints Dr. Alexandre Kaoukhov to Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Feb 2021
Almirall announces Gianfranco Nazzi as new CEO
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 15 Dec 2020
Almirall announces FDA approval of Klisyri(R) (tirbanibulin), a new innovative topical treatment for actinic keratosis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 11 Nov 2020
Pablo Alvarez appointed to President and GM of Almirall US
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2020
Almirall Announces FDA Approval Of Updated Label For Seysara(R) (Sarecycline) Tablets
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 9 Jan 2020
Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 9 Oct 2018
Mike McDonald Joins Synergy MedSales as Chief Financial Officer
Devices Dermatology Personnel Distribution
 HSMN NewsFeed - 21 Sep 2018
Almirall acquires Allergan U.S. medical dermatology portfolio*
Biopharmaceuticals Dermatology Acquisitions
 HSMN NewsFeed - 6 Sep 2017
Pulmatrix Licenses Inhaled COPD Drug PUR0200 to Vectura Group plc
Biopharmaceuticals Licensing
 HSMN NewsFeed - 24 May 2017
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 15 Feb 2017
Aqua Pharmaceuticals Bolsters Executive Team With Three New Hires
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 14 Jun 2016
Suneva Medical Closes $25 Million Financing To Support Continued Growth Opportunities
Devices Dermatology Venture Capital
 HSMN NewsFeed - 22 Feb 2016
Cipher Pharmaceuticals Inc. announces Canadian launch of Actikerall(TM)
Biopharmaceuticals Dermatology Product Launch
 HSMN NewsFeed - 27 Oct 2015
Allergan Acquires Rights To Ironwood's CONSTELLA(R) (Linaclotide) From Almirall In More Than 40 Countries
Biopharmaceuticals Gastroenterology Acquisitions
 HSMN NewsFeed - 19 Aug 2014
Aqua Pharmaceuticals, LLC Welcomes Nathan Mitchell as Senior Director, Marketing
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 28 Jul 2014
Aqua Pharmaceuticals, LLC Announces the U.S. Food and Drug Administration (FDA) Approval of ACTICLATE(TM) (doxycycline hyclate USP) Tablets, 150 mg and 75 mg
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jan 2014
Ipsen and GW Pharmaceuticals plc Enter into Agreement for Ipsen to Promote and Distribute Sativex(R) in Latin America
Biopharmaceuticals Neurology Distribution
 HSMN NewsFeed - 8 Jan 2014
Ironwood Pharmaceuticals Announces Alignment of Workforce with Priority Growth Platforms
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 27 Nov 2013
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 22 Jul 2013
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jul 2013
GW Pharmaceuticals plc Announces Sativex(R) Launch in Italy
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 28 Nov 2012
Constella(R) (linaclotide) Approved in Europe for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 7 Jan 2010
Forest and Almirall Announce Positive Results from the ACCORD COPD I Phase III Study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals
 HSMN NewsFeed - 4 May 2009
Ironwood Announces Linaclotide European Licensing Agreement with Almirall
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 3 Sep 2008
Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Shire Divests Non-Core Product Portfolio to Almirall
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 8 Aug 2007
Victor P. Micati Joins OLIGOMERIX's Board of Directors
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
Almirall
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.